Starting April 1, 2026, Ontario's health insurance plan implemented significant restrictions on bone mineral density (BMD) testing that are preventing patients with osteoporosis from getting the monitoring they need. The new rules limit follow-up bone density scans to once every 36 months for most patients, even when doctors believe earlier testing is medically necessary. Osteoporosis Canada, the country's leading bone health organization, says these restrictions contradict current clinical guidelines and could put vulnerable patients at risk of undetected bone loss and preventable fractures .

What Changed in Ontario's Bone Density Testing Rules?

Before April 2026, Ontario physicians had flexibility in determining how often their patients needed bone density testing. Doctors could order follow-up scans as frequently as every 12 months for high-risk patients if they believed it was clinically appropriate. This allowed individualized care based on each patient's specific situation and disease progression .

The new Ontario Health Insurance Plan (OHIP) Schedule of Benefits changed this approach dramatically. Now, follow-up bone density testing is permitted only once every 36 months for patients with a 10-year fracture risk above 15%, which OHIP defines as "high risk." The only exception is for patients with a specific endocrine condition called Cushing's syndrome or those taking high-dose prednisone (more than 20 mg daily), who can still get tested annually .

This one-size-fits-all approach eliminates the clinical judgment that doctors previously used to identify which patients needed more frequent monitoring. According to Osteoporosis Canada, this creates a significant gap in care for patients with secondary causes of bone loss, those who have suffered new fractures, or those starting medications known to accelerate bone loss .

Who Is Most Affected by These Testing Restrictions?

The new rules create particular challenges for several groups of patients. Those with secondary causes of osteoporosis, such as hyperparathyroidism or rheumatoid arthritis, will now wait 36 months between tests even though these conditions cause rapid bone loss. Similarly, patients starting medications like aromatase inhibitors (used in breast cancer treatment) or androgen deprivation therapy (used in prostate cancer treatment) will face the same 36-month waiting period, despite evidence that these drugs accelerate bone loss .

Patients who experience a new fragility fracture face another problem: if they had a bone density test within the past three years, they may not qualify for a follow-up scan even though a fracture is a clear sign of disease progression. Additionally, patients transitioning off certain bone-building medications may be at increased risk of rapid bone loss but won't have access to earlier testing to monitor this change .

Osteoporosis Canada emphasized that these changes disproportionately affect women, since osteoporosis and fragility fractures are more common in women than men .

What Do Experts Say About the Clinical Impact?

Osteoporosis Canada's position statement, developed by a team of leading bone health specialists, directly challenges the new restrictions. The organization noted that while the 2023 Osteoporosis Canada Clinical Practice Guideline does recommend repeat BMD testing every three years for patients on osteoporosis medications or those with high fracture risk, the guideline includes an important caveat that OHIP's new rules overlook .

"BMD testing should be reassessed earlier if patient develops secondary causes, new fracture or other risk factor for rapid bone loss," the guideline states.

Osteoporosis Canada 2023 Clinical Practice Guideline

By ignoring this critical exception, OHIP's new policy prevents doctors from monitoring disease progression in exactly the patients who need it most. Osteoporosis Canada does not believe the current access outlined by OHIP is consistent with evidence-based clinical practice or in the best interests of patient care .

What Are the Real-World Consequences for Patients?

The practical impact of these restrictions is significant. Patients who genuinely need earlier monitoring are now vulnerable to preventable bone loss that could have been identified and treated sooner. This may result in delays in addressing increasing fracture risk. Some patients will either go without essential testing or be forced to pay out of pocket for private bone density scans .

Doctors also lose the ability to monitor treatment response or disease progression appropriately. The new rules force a standardized approach that eliminates clinical judgment, potentially compromising individualized care. Additionally, BMD tests that were already booked and scheduled within the next 36 months may no longer be covered under the new OHIP guidelines, leaving patients and clinics scrambling to cancel or postpone appointments .

How to Advocate for Your Bone Health During Testing Restrictions

• Document Your Risk Factors: Keep detailed records of any secondary causes of bone loss, new fractures, or medications that accelerate bone loss. Share this information with your doctor to support requests for earlier testing.
• Discuss Your Fracture Risk: Ask your healthcare provider to calculate your 10-year fracture risk using the FRAX tool or similar assessment. Understanding your specific risk level helps you and your doctor plan appropriate monitoring.
• Explore Private Testing Options: If your doctor believes you need earlier testing but OHIP won't cover it, ask about private bone density testing facilities in your area and what out-of-pocket costs might be involved.
• Stay Informed About Policy Changes: Osteoporosis Canada is actively working on advocacy efforts to challenge these restrictions. Monitor their website and contact your provincial representatives to voice concerns about access to necessary medical testing.

What Is Osteoporosis Canada Doing About This?

Osteoporosis Canada has made clear that it does not support the current OHIP restrictions. The organization is calling for several changes: repeat BMD testing in 12 months should be allowed for patients with secondary causes of osteoporosis, new fractures, or other risk factors for rapid bone loss, not just those with Cushing's syndrome or high-dose glucocorticoid use .

The organization is also advocating for deferring any changes to BMD testing policies until evidence-based expert advice is incorporated into OHIP policies, and to give all stakeholders more time to adapt their clinical practices. Members of Osteoporosis Canada's Scientific Advisory Council are in contact with the Ontario Medical Association and Ontario Association of Radiology to discuss coordinated advocacy efforts, and a meeting with representatives from Ontario's Ministry of Health is being arranged .

Why Bone Density Testing Matters for Osteoporosis Management

Bone mineral density testing is the standard way doctors assess bone strength and monitor whether osteoporosis treatment is working. For patients on medications to prevent bone loss or build new bone, regular monitoring helps doctors determine if the treatment is effective or if adjustments are needed. For patients with secondary causes of bone loss or those at high risk of fractures, frequent monitoring can catch rapid bone loss early, before a fracture occurs .

The ability to order testing based on clinical judgment allows doctors to respond quickly when they notice concerning changes in a patient's bone health status. The new restrictions remove this flexibility, potentially allowing serious bone loss to progress undetected between the mandated 36-month testing intervals.

If you live in Ontario and have osteoporosis or risk factors for bone loss, talk with your healthcare provider about how these new testing restrictions might affect your care. Ask whether you qualify for the limited exceptions to the 36-month rule, and discuss what monitoring options are available to you.